Education
About Us
Working with TipRanks
Follow Us
Biotricity (BTCY)
:BTCY
BTCY Stock Chart & Stats
$0.50
-$0.09(-17.87%)
At close: 4:00 PM EST
$0.50
-$0.09(-17.87%)
Day’s Range― - ―
52-Week Range$0.23 - $0.83
Previous CloseN/A
Volume50.15K
Average Volume (3M)34.26K
Market Cap
$9.51M
Enterprise Value$41.98M
Total Cash (Recent Filing)$308.46K
Total Debt (Recent Filing)$13.47M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Feb 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding27,797,710
10 Day Avg. Volume61,294
30 Day Avg. Volume34,255
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.53
P/FCF Ratio-3.07
Enterprise Value/Market Cap4.42
Enterprise Value/Revenue2.78
Enterprise Value/Gross Profit3.49
Enterprise Value/Ebitda-161.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross MarginGross margin expanded to 80.4% driven by an 84% subscription mix that captures the scale benefits of fixed cloud-hosting and cellular data contracts.
Patent AcquisitionPatent acquisition enhances Biotricity’s competitive profile in multi-sensor monitoring.
Product InnovationProduct innovation remains a catalyst as the next-generation, cellular-enabled Biocore Pro gains traction, and strategic partnerships extend Biotricity’s remote monitoring algorithms into new markets.
Bears Say
Neutral RatingWhile there is stable growth and a bullish outlook, a Neutral rating is maintained as expansion consistency, initiative outcomes, and respective financial impact are monitored.
Small-Cap RisksAn investment in Biotricity is subject to the risks inherent in all small-cap companies, including dilution, end-market product acceptance and pricing, and competition against companies with greater resources.
Biotricity News
BTCY FAQ
What was Biotricity’s price range in the past 12 months?
Biotricity lowest stock price was $0.23 and its highest was $0.83 in the past 12 months.
What is Biotricity’s market cap?
Biotricity’s market cap is $9.51M.
When is Biotricity’s upcoming earnings report date?
Biotricity’s upcoming earnings report date is Feb 17, 2026 which is in 64 days.
How were Biotricity’s earnings last quarter?
Biotricity released its earnings results on Nov 14, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.05.
Is Biotricity overvalued?
According to Wall Street analysts Biotricity’s price is currently Overvalued.
Does Biotricity pay dividends?
Biotricity does not currently pay dividends.
What is Biotricity’s EPS estimate?
Biotricity’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biotricity have?
Biotricity has 27,797,710 shares outstanding.
What happened to Biotricity’s price movement after its last earnings report?
Biotricity reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went up 7.547%.
Which hedge fund is a major shareholder of Biotricity?
Currently, no hedge funds are holding shares in BTCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biotricity
Biotricity Inc. (BTCY) is a medical technology company that specializes in the development and commercialization of remote biometric monitoring solutions. The company focuses on delivering innovative, real-time remote monitoring solutions for chronic conditions and lifestyle improvement. Its core product, Bioflux, is a mobile cardiac telemetry device that provides continuous, real-time monitoring for patients with cardiac conditions, enhancing the capabilities of healthcare providers to diagnose and manage these conditions effectively.
BTCY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, improved gross profit, and positive EBITDA, indicating progress towards profitability. Despite a net loss and increased operating expenses, the strategic advancements and positive financial trends suggest a strong positive outlook.View all BTCY earnings summariesTechnical Analysis
Vivos Therapeutics
―
Adagio Medical Holdings
―
Inspira Technologies Oxy BHN
―
Tivic Health Systems
―
Heart Test Laboratories, Inc.
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.17% Other Institutional Investors
99.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---